BGI Genomics Co., Ltd. (300676.SZ)
- Previous Close
48.27 - Open
47.60 - Bid 49.46 x --
- Ask 49.47 x --
- Day's Range
48.20 - 49.99 - 52 Week Range
33.33 - 70.30 - Volume
5,658,736 - Avg. Volume
10,664,259 - Market Cap (intraday)
20.554B - Beta (5Y Monthly) 0.86
- PE Ratio (TTM)
-- - EPS (TTM)
-2.35 - Earnings Date --
- Forward Dividend & Yield 0.10 (0.20%)
- Ex-Dividend Date Jul 4, 2024
- 1y Target Est
52.19
BGI Genomics Co., Ltd. provides genomic sequencing and proteomic services in China and internationally. The company offers solutions to various applications, such as basic research covering human, plant, animal, and microbial species; clinical research in human health; genetic testing and screening; drug discovery and development; and agriculture and biodiversity preservation and sustainability. It provides DNA, RNA, and customized sequencing solutions; and mass spec services, as well as COVID-19 PCR test kits and COVID lab solutions. In addition, the company offers diagnostics and precision medicines for COVID-19, infectious diseases, and oncology. It serves academic institutions, pharmaceutical companies, health care providers, and other organizations. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. BGI Genomics Co., Ltd. was founded in 1999 and is headquartered in Shenzhen, China. BGI Genomics Co., Ltd operates as a subsidiary of BGI Group.
www.bgi.com3,702
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 300676.SZ
View MorePerformance Overview: 300676.SZ
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300676.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300676.SZ
View MoreValuation Measures
Market Cap
20.55B
Enterprise Value
17.29B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.49
Price/Book (mrq)
2.26
Enterprise Value/Revenue
4.65
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-26.03%
Return on Assets (ttm)
-4.10%
Return on Equity (ttm)
-10.16%
Revenue (ttm)
3.72B
Net Income Avi to Common (ttm)
-967.79M
Diluted EPS (ttm)
-2.35
Balance Sheet and Cash Flow
Total Cash (mrq)
4.31B
Total Debt/Equity (mrq)
10.06%
Levered Free Cash Flow (ttm)
-1.16B